Case n./age/sex |
BCVA 1
(RE/LE)
|
BCVA 2
(RE/LE)
|
DMARDs 1 |
DMARDs 2 |
Infliximab therapy |
Adverse effects to infliximab |
1/30/M |
HM/1 |
HM/1.3 |
AZA/CSA |
AZA/ADA |
Suspended (loss of efficacy) |
no |
2/39/M |
0/1 |
0/1 |
CSA |
CSA |
Continued |
no |
3/28/M |
1/1 |
0/0 |
CSA |
CSA |
Continued |
no |
4/46/F |
HM/HM |
1.79/HM |
CSA |
- |
Continued |
no |
5/23/M |
0.15/0.69 |
0.15/0.69 |
AZA |
AZA |
Continued |
no |
6/30/M |
1/0 |
0.22/0 |
CSA |
Colch/ADA |
Suspended (loss of efficacy) |
no |
7/31/M |
HM/0.3 |
HM/0.045 |
CSA |
- |
Continued |
no |
8/28/F |
0.15 |
0.22 |
AZA |
AZA |
Continued |
no |
9/48/F |
0/2.09 |
0.096/2.09 |
AZA/CSA |
- |
Continued |
no |
10/64/F |
1.48 |
HM |
CSA |
- |
Continued |
no |
11/49/F |
0.22/0.39 |
0.3/0.15 |
CSA/Colch |
AZA/Colch |
Continued |
no |
12/49/M |
0/0.045 |
0/0.045 |
CSA |
- |
Continued |
no |
13/43/M |
0.045/0.15 |
0.045/0.69 |
AZA/CSA |
AZA/ADA |
Suspended (loss of efficacy) |
no |
14/61/F |
0.22/0.69 |
0.22/0.69 |
CSA |
CSA |
Continued |
no |
15/42/M |
0 |
0 |
AZA/CSA |
CSA/ INFα |
Suspended (adverse effect) |
acute bronchitis |
16/48/F |
0.69 |
1 |
CSA |
CSA/ADA |
Suspended (adverse effect/loss of efficacy) |
acute bronchitis |
17/32/M |
0/0.39 |
0.22/1 |
CSA |
CSA/INFα |
Suspended (lack of effect) |
no |
18/71/F |
1/0.3 |
1/0.3 |
CSA |
MTX |
Continued |
no |
19/65/F |
0/0.3 |
0/0.096 |
AZA |
AZA/ |
Continued |
no |
20/20/M |
1.79/1.3 |
1/1 |
AZA/CSA |
AZA |
Continued |
no |
21/26/M |
0.096/0.096 |
0/0 |
AZA |
- |
Continued |
no |
22/47/F |
HM/1 |
HM/1 |
AZA/CSA |
AZA |
Continued |
no |
23/32/M |
0.15 |
0.15 |
CSA |
- |
Continued |
no |
24/28/M |
0.69 |
0.69 |
AZA |
AZA |
Continued |
no |
25/62/F |
1.79/1.79 |
1.48/1.79 |
AZA/CSA |
AZA |
Continued |
no |
26/34/M |
0.096 |
0.096 |
CSA |
AZA |
Continued |
no |
27/37/M |
1.79/1.79 |
1.48/1.79 |
AZA |
MTX |
Continued |
no |
28/56/M |
0.69/1.79 |
1.79/2.09 |
CSA |
- |
Continued |
no |
29/57/M |
2.09/1 |
2.09/1.79 |
CSA |
Colch/ADA |
Suspended (loss of efficacy) |
no |
30/32/M |
0/0.096 |
-0.04/0.045 |
AZA/CSA |
- |
Continued |
no |
31/13/M |
0.39 |
0.39 |
CSA |
CSA/ADA |
Suspended (loss of efficacy) |
no |
32/34/M |
1.79/0.15 |
HM/0.045 |
CSA |
CSA |
Continued |
no |